HK Stock Market Move | UNITED LAB(03933) rose by more than 5% after its UBT251 injection for CKD indications received FDA approval for new drug clinical trials.

UNITED LAB (03933) rose by over 5%, as of the time of reporting, it has increased by 5.21%, reaching 13.72 Hong Kong dollars with a trading volume of 1725.01 million Hong Kong dollars. On the news front, UNITED LAB announced that its wholly-owned subsidiary Federal Biotech (Zhuhai Hengqin) Co., Ltd has obtained approval from the U.S. Food and Drug Administration (FDA) to conduct Phase II clinical trials for its innovative drug UBT251 injection, developed independently for the treatment of chronic kidney disease (CKD). Previously, the CKD indication had received clinical trial approval from the China National Medical Products Administration on January 20, 2025. UBT251 is a long-acting GLP-1 / GIP / GCG triple-target receptor agonist synthesized using chemical peptide methods. The company is the first in China and the second globally to receive approval for clinical trials of a long-acting GLP-1 / GIP / GCG triple agonist prepared by chemical peptide synthesis. Currently, multiple indications such as adult type 2 diabetes, overweight or obesity, CKD, etc. have been approved for clinical trials in both China and the United States, and have already entered the clinical trial phase in China.